Psoriasis

In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Dual-layer microneedle patch delivers fast itch relief and sustained methotrexate-zinc therapy, improving psoriasis inflammation, immune balance, and infection protection in mice.

Oral peptide drugs move beyond injections, bringing targeted psoriasis therapy like icotrokinra and reshaping dermatology’s treatment options.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

Oral therapies at AAD 2026 are closing the efficacy gap with biologics, with two TYK2 inhibitors and an oral IL-23 peptide each delivering clearance rates once thought possible only with injectables.

At EULAR 2026, investigators presented head-to-head data demonstrating significantly higher joint response rates with bimekizumab compared with risankizumab in PsA.

Dermatology Times' editor in chief highlights essential late-breaker data from AAD 2026, including upadacitinib, rezpegaldesleukin, icotrokinra, zasocitinib, envudeucitinib, sonelokimab, and more.

Investigators reported that individualized adalimumab dose adjustments based on serum drug levels could increase clinical response rates compared with standard dosing.

Dutch registry data show obesity and smoking predict higher psoriatic arthritis activity, making weight loss and quitting key to better control.

The analysis highlights potential disease-specific effects of GLP-1 pathway modulation across inflammatory conditions.

In this episode, Liza O'Dowd, MD, discusses the 52-week data from the ICONIC clinical program of icotrokinra, the most recently approved oral peptide agent for psoriasis.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

Patients who are needle-averse may soon have effective non-injectable options with biologic-like results.

A new review examined the bone–vascular axis in psoriasis and how the current therapeutic toolbox can influence cardiovascular and skeletal health.

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

At AAD 2026, Andrew Blauvelt, MD, presented robust PASI responses and favorable safety from ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation TYK2 inhibitor.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.

LEO Pharma shared 2 posters with data from the ongoing EFFISAYIL ON program, supporting long-term use of spesolimab for generalized pustular psoriasis.

At AAD 2026, Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.